If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-21. Numbers and descriptions here follow the published literature rather than marketing material.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
6 – he won against Oscar Otte, Roman Safiullin, Laslo Đere, Kei Nishikori and Alejandro Davidovich Fokina. In the semifinal, he played Stefanos Tsitsipas, to whom he lost after a 5-set battle. Zverev's first appearance on grass started with a tournament at home in Halle – he lost in the second round to the eventual tournament winner Ugo Humbert. At Wimbledon, seeded No. 4, he equaled his best achievement at the tournament to date – reaching the fourth round for a second time. Along the way he defeated Tallon Griekspoor, Tennys Sandgren and Taylor Fritz. He was defeated in the fourth round by Félix Auger-Aliassime in five sets. Following this run he returned to the top 5 after 2 years on 12 July 2021. At the Olympics, Zverev beat Yen-hsun Lu, Daniel Elahi Galán, Nikoloz Basilashvili and Jérémy Chardy to reach the semifinals. In the semifinals, despite being a set and a break down against world No. 1 Novak Djokovic, Zverev rallied to break back and won eight games in a row on his way to win in three sets. He defeated Karen Khachanov in straight sets in the final to claim the Olympic gold medal. Zverev became the first German man to win a gold medal in singles and the first to win a medal since Tommy Haas won his silver medal at the 2000 Sydney Olympics. Following the Olympics, Zverev reached his second Masters 1000 final of the year at the 2021 Western & Southern Open after defeating Lloyd Harris, Guido Pella, Casper Ruud and Stefanos Tsitsipas after a close three-set battle in the semifinal. Zverev had not won a match at the tournament in six prior appearances.
In June 1659, the two armies met near the town of Konotop. One army comprised Cossacks, Tatars, and Poles, and the other was led by a top Muscovite military commander of the era, Prince Aleksey Trubetskoy. After terrible losses, Trubetskoy was forced to withdraw to the town of Putyvl on the other side of the border. The battle is regarded as one of the Zaporizhian Cossacks' most impressive victories. In 1659, Yurii Khmelnytsky was elected hetman of the Zaporizhian Host/Hetmanate, with the endorsement of Moscow and supported by common Cossacks unhappy with the conditions of the Union of Hadiach. In 1660, however, the hetman asked the Polish king for protection, leading to the period of Ukrainian history known as The Ruin.
==== High-temperature creep and flammability ==== Magnesium's tendency to creep (gradually deform) at high temperatures is greatly reduced by alloying with zinc and rare-earth elements. Flammability is significantly reduced by a small amount of calcium in the alloy. By using rare-earth elements, it may be possible to manufacture magnesium alloys that are able to not catch fire at higher temperatures compared to magnesium's liquidus and in some cases potentially pushing it close to magnesium's boiling point.
=== Hysteresis === Hysteresis, in this case, refers to the restructuring of the adhesive interface over some period of time, with the result being that the work needed to separate two surfaces is greater than the work that was gained by bringing them together (W > γ1 + γ2). For the most part, this is a phenomenon associated with diffusive bonding. The more time is given for a pair of surfaces exhibiting diffusive bonding to restructure, the more diffusion will occur, the stronger the adhesion will become. The aforementioned reaction of certain polymer-on-polymer surfaces to ultraviolet radiation and oxygen gas is an instance of hysteresis, but it will also happen over time without those factors. In addition to being able to observe hysteresis by determining if W > γ1 + γ2 is true, one can also find evidence of it by performing "stop-start" measurements. In these experiments, two surfaces slide against one another continuously and occasionally stopped for some measured amount of time. Results from experiments on polymer-on-polymer surfaces show that if the stopping time is short enough, resumption of smooth sliding is easy. If, however, the stopping time exceeds some limit, there is an initial increase of resistance to motion, indicating that the stopping time was sufficient for the surfaces to restructure.
Sources: en.wikipedia.org
== Natural occurrences == Caffeic acid can be found in the bark of Eucalyptus globulus, the barley grain Hordeum vulgare, and the herb Dipsacus asperoides. It can also be found in the freshwater fern Salvinia molesta and in the mushroom Phellinus linteus.
== Chemical reaction == The two substrates of this enzyme are the luciferin, coelenterazine and oxygen. Its products are the oxyluciferin, coelenteramide, carbon dioxide, and a photon. It belongs to the family of oxidoreductases, specifically those acting on single donors with O2 as oxidant and initial incorporation of two atoms of oxygen into the substrate. Although the enzyme is part of the group of enzymes that act on coelenterazine, such as Renilla and Gaussia luciferases, it does not share base pair sequences with these enzymes. OpLuc catalyzes the ATP independent chemical reaction:
reaction mechanism The step-by-step sequence of elementary reactions by which a larger chemical reaction or overall change occurs. A complete mechanism must describe and explain which bonds are broken and which are formed (and in what order), as well as all reactants, products, and catalysts involved; the amounts of each; all intermediates, activated complexes, and transition states; and the stereochemistry of each chemical species. Because the detailed processes of a complex reaction are not observable in most cases, a reaction mechanism is often a theoretical conjecture based on thermodynamic feasibility and what little support can be gained from experiment.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.